Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available for viewing.
Arecor featured by the highly regarded industry publication, Scrip
This excellent feature came out shortly after the Company announced that it had filed a Clinical Trial Application (CTA) to conduct a Phase I study in Diabetes Type 1 patients of its ultra-rapid acting insulin product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection and the filing represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.
Advancing today's therapies to enable healthier lives.
Arecor Therapeutics Plc